Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions
Jayesh Desai(Peter MacCallum Cancer Centre), George D. Demetri(American Society of Clinical Oncology), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Annick D. Van den Abbeele(Unknown), Eric vanSonnenberg(University of Arizona), Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Harvard University), Stuart G. Silverman(Brigham and Women's Hospital), S. Shankar(Brigham and Women's Hospital), Kemal Tuncali(Brigham and Women's Hospital)
Cited by 20
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716